PPP3CA
Protein phosphatase 3 catalytic subunit alpha
As of the edition of 20 October 2026, PPP3CA (protein phosphatase 3 catalytic subunit alpha, UniProt Q08209) has 1 drug tested at it and 3 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q08209
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 21
- Disease areas
- Immune system; Pregnancy and women's health; Skin and connective tissue; Urinary and reproductive; Eye; Infections; Lungs and airways
- Registered trials of its drugs
- 21
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Voclosporin | Marketed | Phase 4 | Ends 2027 |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Engaged | 1 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Aurinia Pharmaceuticals | Route B |
| Otsuka | Route B |
The other 1 company at PPP3CA
In the product3 companies in all; 1 is not named here, and no score is.
See the 3 companies at PPP3CA, ranked, with the facts behind eachRequest access. Nothing is shown until you do.